SAB Biotherapeutics (NASDAQ:SABS) Announces Quarterly Earnings Results

Key Points

• SAB Biotherapeutics reported a quarterly loss of $0.24 per share, beating analysts’ consensus estimate of a $0.27 loss per share.
• Its SAFEGUARD trial has fully enrolled adult and adolescent cohorts, with enrollment expected to finish in Q4 2026 and top-line results anticipated in the second half of 2027. The FDA also granted Fast Track designation to SAB-142.
• The company ended the quarter with $205 million in cash and investments, which it expects to fund operations through 2028; however, R&D and administrative costs rose, and it reported a $22.3 million net loss.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03, FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics' conference call:

• SAFEGUARD enrollment is progressing: adult and adolescent cohorts are fully enrolled and closed to screening, and SAB Bio expects to complete enrollment in Q4 2026. Top-line data are expected in the second half of 2027.
• The FDA granted Fast Track designation to SAB-142, which may allow more frequent FDA interactions and rolling review of a future BLA; the designation does not guarantee approval or change the approval standard.
• The investigator-led PRISE study expects to dose its first patient in Q4 2026 and will evaluate SAB-142 in patients diagnosed up to two years earlier. Management sees the study as a potential path to expanding the eligible population, but did not provide a data timeline.
• SAB Bio reported $205 million in cash, cash equivalents and investment securities at quarter-end and said its cash should fund operations through 2028, including the planned PRISE expenses.
• Quarterly R&D and G&A expenses rose to $18.1 million and $7.8 million, respectively, as the company advanced its clinical program; SAB Bio reported a $22.3 million net loss versus net income a year earlier, when results included a large warrant-liability fair-value gain.

SAB Biotherapeutics Trading Down 7.5%

SAB Biotherapeutics stock traded down $0.24 during mid-day trading on Thursday, reaching $2.94. 293,144 shares of the company were exchanged, compared to its average volume of 669,102. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.22 and a quick ratio of 9.22. The company has a fifty day simple moving average of $3.21 and a 200-day simple moving average of $3.67. SAB Biotherapeutics has a 12 month low of $2.44 and a 12 month high of $5.15.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on SABS shares. Weiss Ratings raised SAB Biotherapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 17th. Wall Street Zen raised SAB Biotherapeutics from a "strong sell" rating to a "sell" rating in a report on Monday, August 10th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $12.00.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals' plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.